« Previous  |  Next »

Vioxx Risks Could Have Been Detected In 2000

That’s according to a new analysis that shows there was an association between the Merck drug and cardiovascular risk as early as December 2000. Vioxx, you may recall, was withdrawn in September 2004, after mounting debate about heart risks linked to ...

From ED SILVERMAN, Pharmalot,  23 Nov 2009

Related Topics: Merck & Company, Inc.,  U.S. Senate

Texas Court Dismisses State Vioxx Suit Against Merck

The Texas Attorney had filed a lawsuit in 2005 seeking a refund for money the state spent on Merck’s controversial painkiller, which had been withdrawn from the market the previous year over links to heart attacks and strokes. The suit sought damages ...

From ED SILVERMAN, Pharmalot,  23 Nov 2009

Related Topics: Merck & Company, Inc.

Come Again? A Spray For Premature Ejaculation

Before you get ahead of yourself, the spray has not yet been approved by the FDA. But the treatment did delay premature ejacualtion by as much as five times - or an average of 108 seconds - in a study of 256 men. Those whose penis tips were numbed out ...

From ED SILVERMAN, Pharmalot,  23 Nov 2009

Related Topics: US Food and Drug Administration,  Sciele Pharma, Inc.

Pharmalot… Pharmalittle… Good Morning

Hello, everyone. And welcome to a shorter working week, at least here in the states. Although, we suspect the next couple of days will be jam-packed, as everyone tries to squeeze a lot of work into not a lot of time. In any event, time to grab a cup of ...

From ED SILVERMAN, Pharmalot,  23 Nov 2009

Pharmalot… Pharmalittle… The Weekend Nears

Once again, the week is about to draw to a close. And not a moment too soon. Of course, we must still muddle through another deadline or meeting, but relief is in sight. What will you do this weekend? We will, of course, rake more leaves and spend time ...

From ED SILVERMAN, Pharmalot,  20 Nov 2009

Pfizer Wants You To Take Fido To Thanksgiving

Here’s a cynical way to boost drug sales. In a press release that tugs on your heart strings, Pfizer reminds us that some people feel bad about leaving their dog at home when they go elsewhere for the holidays. And the drugmaker also notes the family ...

From ED SILVERMAN, Pharmalot,  19 Nov 2009

Related Topics: Pfizer Inc.,  Oliver Hardy

Lilly’s Departing R&D Chief Gets A $2M Payout

Just as the big drugmaker gets set to slash some 5,500 jobs as part of a mammoth restructuring, the outgoing head of R&D, Steve Paul, is getting a handsome, $2 million severance payout. The 59-year-old Paul, who joined Lilly in 1993 and has headed its ...

From ED SILVERMAN, Pharmalot,  19 Nov 2009

EU Wants Details On Brand Name & Generic Deals

European regulators will ask brand-name drugmakers for details of their deals with generic companies as part a crackdown on firms suspected of blocking cheaper treatments, a European Commission official disclosed, according to Reuters. Last July, you ...

From ED SILVERMAN, Pharmalot,  19 Nov 2009

Related Topics: European Commission,  European Union

Grassley Presses Medical Schools On Ghostwriting

This is the thinking - if a college student submits a paper written by someone else, it’s considered plagiarism. But what is it called when an academic researcher submits a journal study that was written, shaped or heavily edited by a medical ...

From ED SILVERMAN, Pharmalot,  18 Nov 2009

Related Topics: U.S. Republican Party,  U.S. Senate,  New York Times Company,  Harvard University,  Johns Hopkins

Following Fred: How Hassan Will Spend His Time

Now that Fred Hassan is no longer the chief executive of Schering-Plough - or any other drugmaker - since Merck finally scooped up its rival, Fred has been busy accepting invitations to join the boards of various other corporations. Apparently, his ...

From ED SILVERMAN, Pharmalot,  18 Nov 2009

Related Topics: Schering Plough Corp,  Merck & Company, Inc.

« Previous  |  Next »

Who is This?

Help us add to our database, by linking this writer their entry in Wikipedia or Source Watch, or by suggesting that we remove it from our index.

Suggest an Entry